Tiny study hopes to predict blood cancer risk from genetic mutations

NCT ID NCT02804984

Terminated Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to find genetic mutations in people with idiopathic cytopenia of undetermined significance (ICUS), a condition of unexplained low blood cell counts. Researchers wanted to see if these mutations are similar to those found in myelodysplastic syndrome (MDS), a type of blood cancer, suggesting ICUS could be an early stage of MDS. Only 2 participants were enrolled before the study was terminated, so the findings are very limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help identify which patients with unexplained low blood counts are at risk of developing myelodysplastic syndrome (MDS), enabling earlier monitoring or intervention.
What could go wrong: The study was terminated early with only 2 participants, so results are very limited. It is a small, observational genetic analysis, not a treatment trial, so no direct benefit to patients is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

CHU Amiens

Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.